Clinical Trial Update: A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) [Phase 3]

View source ↗

Summary

This clinical trial update reports on RELAY, a Phase 3 study evaluating the combination of ramucirumab with erlotinib in previously untreated patients with EGFR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cyramza (ramucirumab)
• Tarceva (erlotinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Non-Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-03-04